A decades-old glau­co­ma drug tossed aside by Pfiz­er gets a new life at a small biotech

Months ago, Pfiz­er made a grim an­nounce­ment that it would stop man­u­fac­tur­ing phos­pho­line io­dide, its decades-old “mir­a­cle drug” for a rare form of glau­co­ma. The phar­ma said its in­ven­to­ry would run dry by May 2021, leav­ing some pa­tients with few op­tions short of surgery.

But af­ter snag­ging the rights and the rest of Pfiz­er’s sup­ply, a small New York biotech is look­ing to give phos­pho­line io­dide new life.

Pfiz­er is hand­ing over the drug’s NDA and trade­mark to Fera Phar­ma­ceu­ti­cals, a Lo­cust Val­ley, New York-based com­pa­ny run by for­mer San­doz US CEO Frank Del­laFera, the phar­ma said in a state­ment on Mon­day.

While Fera de­clined a re­quest for com­ment, Del­laFera shared this gen­er­al state­ment re­gard­ing the com­pa­ny’s vi­sion on its web­site: “Our goal is sim­ple — to keep more qual­i­ty health­care choic­es alive for the peo­ple who need them.”

Phos­pho­line io­dide was ap­proved back in 1960, and un­til re­cent­ly was man­u­fac­tured by Pfiz­er to treat apha­kic glau­co­ma, a rare con­di­tion that can oc­cur af­ter cataract surgery. The dis­ease is as­so­ci­at­ed with poor con­trol of in­traoc­u­lar pres­sure, and fail­ure to low­er that pres­sure can re­sult in blind­ness. With­out med­ica­tion to do so, some pa­tients must re­sort to surgery.

“For the few pa­tients I have on it, noth­ing but surgery could re­place it,” one cataract and glau­co­ma sur­geon post­ed on Twit­ter back in May.

Pfiz­er cit­ed sup­ply chain is­sues and a de­cline in pa­tient use as the rea­son why it de­cid­ed to stop mak­ing phos­pho­line io­dide. The com­plex sup­ply chain has be­come in­creas­ing­ly un­sta­ble over the years, the com­pa­ny said, adding that about 100 pa­tients use the drug cur­rent­ly in the US.

Last month, the FDA agreed to ex­tend the drug’s ap­proved shelf life from 24 to 36 months, adding an ad­di­tion­al year to the la­bel to ad­dress short-term short­ages. And ac­cord­ing to Pfiz­er, Fera has “the ca­pa­bil­i­ties, ex­pe­ri­ence, and mo­ti­va­tion to bring P.I. to pa­tients on a sus­tain­able and ex­pe­dit­ed ba­sis.”

Both Pfiz­er and Fera de­clined to com­ment on the fi­nan­cial terms of the deal. Some wor­ry the new own­er­ship could lead to price hikes for the drug, which cur­rent­ly costs around $100 per 5ml, ac­cord­ing to drugs.com.

Pfiz­er says it will pro­vide con­sul­ta­tion ser­vices to Fera, though it’s un­clear what the com­pa­ny’s plans are go­ing forth — or if it will be able to avoid the same man­u­fac­tur­ing is­sues that haunt­ed Pfiz­er.

So­cial cred­it: AP Im­ages

Has the mo­ment fi­nal­ly ar­rived for val­ue-based health­care?

RBC Capital Markets’ Healthcare Technology Analyst, Sean Dodge, spotlights a new breed of tech-enabled providers who are rapidly transforming the way clinicians deliver healthcare, and explores the key question: can this accelerating revolution overturn the US healthcare system?

Key points

Tech-enabled healthcare providers are poised to help the US transition to value, not volume, as the basis for reward.
The move to value-based care has policy momentum, but is risky and complex for clinicians.
Outsourced tech specialists are emerging to provide the required expertise, while healthcare and tech are also converging through M&A.
Value-based care remains in its early stages, but the transition is accelerating and represents a huge addressable market.

Clay Siegall, Morphimmune CEO

Up­dat­ed: Ex-Seagen chief Clay Sie­gall emerges as CEO of pri­vate biotech

Clay Siegall will be back in the CEO seat, taking the helm of a private startup working on targeted cancer therapies.

It’s been almost a year since Siegall resigned from Seagen, the biotech he co-founded and led for more than 20 years, in the wake of domestic violence allegations by his then-wife. His eventual successor, David Epstein, sold the company to Pfizer in a $43 billion deal unveiled last week.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.

Paul Song, NKGen Biotech CEO

NK cell ther­a­py-fo­cused biotech eyes SPAC deal

A small, Santa Ana-based biotech created in 2017 is looking to enter a SPAC deal as it lays out plans to begin trials in its lead cell therapy candidates and bring on new executives.

Graf Acquisition Corp. IV and NKGen Biotech announced Thursday, with few other details, that the two companies signed a non-binding letter of intent to “pursue a business combination.” Graf Acquisition II and III withdrew their IPOs last year.

Zhi Hong, Brii Biosciences CEO

Brii Bio­sciences stops man­u­fac­tur­ing Covid-19 an­ti­body com­bo, plans to with­draw EUA re­quest

Brii Biosciences said it will stop manufacturing its Covid-19 antibody combination, sold in China, and is working to withdraw its emergency use authorization request in the US, which it started in October 2021.

The Beijing and North Carolina biotech commercially launched the treatment in China last July but is now axing the work and reverting resources to other “high-priority programs,” per a Friday update. The focus now is namely hepatitis B viral infection, postpartum depression and major depressive disorders.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.

FDA ad­vi­sors unan­i­mous­ly rec­om­mend ac­cel­er­at­ed ap­proval for Bio­gen's ALS drug

A panel of outside advisors to the FDA unanimously recommended that the agency grant accelerated approval to Biogen’s ALS drug tofersen despite the drug failing the primary goal of its Phase III study, an endorsement that could pave a path forward for the treatment.

By a 9-0 vote, members of the Peripheral and Central Nervous System Drugs Advisory Committee said there was sufficient evidence that tofersen’s effect on a certain protein associated with ALS is reasonably likely to predict a benefit for patients. But panelists stopped short of advocating for a full approval, voting 3-5 against (with one abstention) and largely citing the failed pivotal study.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.

Geoff McDonough, Generation Bio president and CEO

Mod­er­na part­ners on non-vi­ral gene ther­a­py with Gen­er­a­tion Bio af­ter swing­ing gene edit­ing deals

Moderna has inked a five-year partnership with gene therapy biotech Generation Bio, it announced Thursday morning, wading deeper into the genetic medicines space as it navigates beyond its vaccine work.

Moderna will pay Generation Bio $40 million upfront and invest another $36 million into the gene therapy biotech. In exchange, Moderna can license Generation Bio’s non-viral gene therapy platforms for two immune cell programs and two liver programs, with an option for a fifth program. Moderna will fund all the research work under the partnership, and could be on the hook for milestone, fee and royalty payments totaling up to $1.8 billion, a company spokesperson tells Endpoints News.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.

Steven James, Pionyr Immunotherapeutics CEO

Gilead pass­es on ful­ly ac­quir­ing Pi­o­nyr, as eyes now turn to Tizona, a fel­low sum­mer 2020 buy­out op­tion

Gilead and Pionyr Immunotherapeutics, a biotech trying to follow up on the first generation of checkpoint inhibitors, have “mutually agreed” on a rewrite to their 2020 terms, with Gilead deciding not to buy out the company.

The California biopharma waived its option to acquire the remaining 50.1% of Pionyr, which would have triggered a $315 million upfront payment and up to $1.15 billion down the road. Had Gilead waited to decide, the drugmaker would have had a potential payment to make in the near term under their agreement, a spokesperson said in an email to Endpoints News.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.

Sergio Traversa, Relmada Therapeutics CEO

Rel­ma­da makes 'crit­i­cal changes' to PhI­II tri­al to try and save de­pres­sion drug

Relmada Therapeutics is making changes to its Phase III study of its lead drug for major depressive disorder, in an attempt to avoid problems with a prior trial that showed little difference between the drug and a placebo.

That failure in October wiped 80% from Relmada’s stock price, and was followed by another negative readout a few months later. In both cases, the company said that there had been trial sites that were associated with what it called surprising placebo effects that skewed the results compared with the drug, REL-1017.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.

In­cyte hit by CRL on ex­tend­ed-re­lease JAK tablets, mud­dy­ing plans for Jakafi fran­chise ex­pan­sion

The FDA has rejected Incyte’s extended-release formulation of ruxolitinib tablets, in a surprise setback for the company’s plans to build on its blockbuster Jakafi franchise.

The ruxolitinib XR tablets are designed to be taken once a day, whereas Jakafi is indicated for twice daily dosage (although some patients can take it once daily).

According to Incyte, the FDA acknowledged in its complete response letter that the study submitted in the NDA “met its objective of bioequivalence based on area under the curve (AUC) parameters but identified additional requirements for approval.”